A higher-than-expected prevalence of gene mutations in Parkinson鈥檚 disease patients suggests genetic testing should be offered to them more broadly, researchers said on Monday in the medical journal Brain.
Genetic profiling performed on more than 8,000 patients of varying races and ethnicities, all with Parkinson's disease, showed 13 per cent had a genetic form of the progressive brain disorder, the researchers found.
That rate was 18 per cent in patients with known risk factors, such as an earlier age at onset, Parkinson鈥檚 disease in a first-degree relative, or certain ancestry such as Ashkenazi Jewish, Spanish Basque or North African Berber.
Among patients with no known risk factors, more than 9 per cent had a predisposing genetic mutation.
With new gene-specific drugs for the disease entering the research pipeline, the implications of the findings are significant, the researchers said.
Previous studies had suggested that about 5 per cent to 10 per cent of Parkinson鈥檚 disease cases were linked with genetic variants 鈥� and most of those studies had been limited to patients with known risk factors.
Presently, only a small fraction of people with Parkinson鈥檚 disease receive genetic testing, largely because neurologists are uncomfortable with their knowledge of Parkinson鈥檚 disease genetics, access to genetic counsellors is limited, and the identification of a genetic basis has been unlikely to impact a patient鈥檚 treatment, said James Beck, senior vice president and chief scientific officer of the Parkinson鈥檚 Foundation, the study鈥檚 sponsor.
But with recent advances, doctors 鈥渁re now on the cusp of figuring out how to treat patients based on genetics,鈥� Beck said.
With trials of gene-specific treatments underway, and genetic results potentially impacting disease prognosis and shedding light on familial risks, clinical genetic testing should be offered to everyone with Parkinson鈥檚 disease, the research team concluded.
(Reporting by Nancy Lapid; editing by Stephen Coates)
